CN103301115A - Medicine composition for treating epilepsy - Google Patents
Medicine composition for treating epilepsy Download PDFInfo
- Publication number
- CN103301115A CN103301115A CN2013102546487A CN201310254648A CN103301115A CN 103301115 A CN103301115 A CN 103301115A CN 2013102546487 A CN2013102546487 A CN 2013102546487A CN 201310254648 A CN201310254648 A CN 201310254648A CN 103301115 A CN103301115 A CN 103301115A
- Authority
- CN
- China
- Prior art keywords
- levetiracetam
- chlocibutamine
- epilepsy
- composition
- treating epilepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for treating epilepsy, belonging to the technical field of medicines. The invention provides a compound medicine composition for treating epilepsy. The composition is characterized in that the composition contains 3,4-dichlorophenyl-propenoyl-sec.-butylamine and levetiracetam. The composition is provided to improve the compliance of patients and achieve the aim of controlling epileptic seizure, and simultaneously reduces the side effects of a clinical medicine of a central nervous system inhibitor. A safe and effective clinical medicine is provided for epilepsy patients.
Description
Technical field: the present invention relates to a kind of compositions for the treatment of epilepsy, belong to medical technical field.
Background technology: epilepsy is the chronic brain diseases that causes owing to Different types of etiopathogenises, thereby causes the transience central nervous system function unusually as feature take the cerebral neuron paradoxical discharge.Document announcement is arranged, domestic Epidemiological study demonstration, the sickness rate of domestic epilepsy is near 1 ‰, and prevalence is about 4 ‰～9 ‰.The existing epileptic of China is nearly more than 5,000,000, and it is main that the best approach of controlling at present epilepsy remains Drug therapy, and its medication purpose is to reduce or stop outbreak.At present, there is no the method for effective prevention and healing, so the treatment of epilepsy is lifelong often, and because there is untoward reaction in most drug, and some side effect or irreversible, life-time service make the patient be difficult to accept, therefore cause the interruption for the treatment of and the state of an illness repeatedly.
Levetiracetam is a kind of pyrrolidinone derivatives, its chemical constitution and existing antiepileptic non-correlation.The definite mechanism of levetiracetam antiepileptic action it be unclear that.
The purpose of this invention is to provide a kind of compositions, improve patient's compliance, reach the purpose of control epilepsy, reduce simultaneously the generation of side effect.For the epileptic provides a kind of safe, effective and inexpensive clinical application.
The applicant finds through overtesting, and chlocibutamine and levetiracetam compatibility are being obtained beyond thought synergism aspect the treatment epilepsy.
Technical scheme:
A kind of compound medicament composition for the treatment of epilepsy is characterized in that, contains chlocibutamine and levetiracetam.
The preferred technical scheme of the present invention is: in the compositions of unit dose, containing levetiracetam is 250～750mg, chlocibutamine 75～200mg.
The preferred technical scheme of the present invention is: in the compositions of unit dose, containing levetiracetam is 300～650mg, chlocibutamine 80～180mg.
The preferred technical scheme of the present invention is: in the compositions of unit dose, containing levetiracetam is 350～550mg, chlocibutamine 80～150mg.
The preferred technical scheme of the present invention is: in the compositions of unit dose, containing levetiracetam is 400～500mg, chlocibutamine 100～150mg.
The conventional amount used of the present composition is oral 1,2 times on the 1st.
Present composition pharmaceutical preparation preparation method preparation routinely.
The present composition can also be prepared as slow releasing preparation.
The present composition can be prepared as controlled release preparation.According to the drug release situation selection unit dosage in the body.
The invention has the beneficial effects as follows provides a kind of compositions, by chlocibutamine and sulfonamides as carbonic anhydrase inhibitors compatibility, is obtaining beyond thought synergism aspect the treatment epilepsy.Under the prerequisite that guarantees therapeutic effect, can reduce the side effect of sulfonamides as carbonic anhydrase inhibitors clinical application, improved clinical therapeutic efficacy.
Embodiment 1, chlocibutamine 200g, levetiracetam 250g prepares 1000 according to a conventional method.
Embodiment 2, chlocibutamine 75g, levetiracetam 750g prepares 1000 according to a conventional method.
Embodiment 3, chlocibutamine 90g, levetiracetam 500g prepares 1000 according to a conventional method.
Embodiment 4, chlocibutamine 100g, levetiracetam 300g prepares 1000 according to a conventional method.
Embodiment 5, chlocibutamine 100g, levetiracetam 400g prepares 1000 according to a conventional method.
Embodiment 6, chlocibutamine 150g, levetiracetam 400g prepares 1000 according to a conventional method.
Embodiment 7, chlocibutamine 80g, levetiracetam 250g prepares 1000 according to a conventional method.
Test example 1:
Enter the group standard: the age met epilepsy class definition (1985) more than 18 years old; Do not treat history, the epilepsy frequency per month 2 times or more than; Confirm to have epileptiform discharge through EEG (electrocardiogram) examination; Be ready to participate in test and preferably compliance is arranged.
Exclusion standard: non-Epileptic fits; Be associated with the serious diseases such as cardiovascular, liver, kidney and hemopoietic system; Medicine and alcohol abuse history are arranged; Prepare gestation or women breast-feeding their children; Affect the treatment or safety judgement person with activeness psychotic etc.
80 examples, male 48 examples, women 32 examples.Be divided at random 8 groups, every group of 10 people are respectively 1 group to 6 groups of chlocibutamine group, levetiracetam group, zonisamide group, embodiment.Continuous use 2 months, during the medication, previous month as the phase of adjustment, get rear one month outbreak situation as the judgement of therapeutic effect.
Observation index: the total inspection phase was 8 weeks.The rehabilitation diary is observed once and checked to per 2 weeks, carry out routine blood test, routine urinalysis, liver, renal function and Electrocardioscopy around every, and EEG (electrocardiogram) examination after the treatment before the treatment, and with regard to epilepsy number of times, drug dose, untoward reaction extremely degree record and curative effect evaluation be once.
The chlocibutamine group is taken the chlocibutamine sheet, 200mg/ sheet, every day 2 times, each 1.
Levetiracetam group: 500mg/ sheet, each 1, every day three times.Initial treatment dosage is each 500mg, every day 2 times, according to toleration, progressively increases to every day 3 times, each 1.
1 group-6 groups of embodiment take the tablet 2 times of corresponding embodiment, each 1 every day.
Judgment criteria: outbreak control, nothing outbreak in the observation period; Produce effects, attack times reduces 75%-99% in the observation period; Effectively, the observation period attack times reduces between 74%-50%; Heterodyne, observation period attack times reduce below the 26%-49%; Invalid, the observation period attack times reduces below 25%; Worsen, attack times increases more than 25%.
Digital proof in the table: the successful of present composition treatment epilepsy is higher than the folk prescription medicine of matched group, illustrates that synergism has occured the reasonable compatibility of chlocibutamine and central nervous system depressant.
Test example 2, the Wang, the woman, 62 years old, clinical definite was the epileptic, and medical history 6 years was once taken phenobarbital, O'Casey equality medicine, can not effectively control outbreak, and patient and family are subjected to the torment of this disease deeply.Before this on-test, take levetiracetam every day 3 times, each 500mg/ sheet, 1,3 months, month attack times was not improved.Through soliciting patient and family members' suggestion, have the phychology of trying in arms, take the embodiment of the invention 7 compositionss, day take medicine 2 times, 1 time 1.Second month plays record morbidity number of times and is month outbreak 5 times.Simultaneously the patient has eliminated basically because of sleepy, the inappetence of taking the other drug appearance, weak, movement disorder, and readme can be felt good.
The above test example proof present composition has outstanding synergy to the treatment epileptic condition.The combination that chlocibutamine and levetiracetam are described has beyond thought clinical result of use.
Claims (4)
1. a compound medicament composition for the treatment of epilepsy is characterized in that, in the compositions of unit dose, containing levetiracetam is 300～650mg, chlocibutamine 80～180mg.
2. described compositions according to claim 1 is characterized in that, in the compositions of unit dose, contains levetiracetam 250～750mg, chlocibutamine 75～200mg.
3. described compositions according to claim 1 is characterized in that, in the compositions of unit dose, contains levetiracetam 350～550mg, chlocibutamine 80～150mg.
4. described compositions according to claim 1 is characterized in that, in the compositions of unit dose, contains levetiracetam 400～500mg, chlocibutamine 100～150mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310254648.7A CN103301115B (en) | 2013-06-15 | 2013-06-15 | A kind of pharmaceutical composition for treating epilepsy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310254648.7A CN103301115B (en) | 2013-06-15 | 2013-06-15 | A kind of pharmaceutical composition for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103301115A true CN103301115A (en) | 2013-09-18 |
| CN103301115B CN103301115B (en) | 2018-03-20 |
Family
ID=49127123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310254648.7A Active CN103301115B (en) | 2013-06-15 | 2013-06-15 | A kind of pharmaceutical composition for treating epilepsy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103301115B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991561A (en) * | 2010-11-11 | 2011-03-30 | 迪沙药业集团有限公司 | 3,4-dichlorophenyl-propenoyl-sec-butylamine composition |
-
2013
- 2013-06-15 CN CN201310254648.7A patent/CN103301115B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991561A (en) * | 2010-11-11 | 2011-03-30 | 迪沙药业集团有限公司 | 3,4-dichlorophenyl-propenoyl-sec-butylamine composition |
Non-Patent Citations (2)
| Title |
|---|
| YI QUAN PEI: "A Review of Pharmacology and Clinical Use of Piperine and Its Derivatives", 《EPILEPSIA》 * |
| 田国红等: "左乙拉西坦-一种具有全新作用机制的抗癫痫新药", 《中国新药与临床杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103301115B (en) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yousef et al. | A double‐blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component | |
| JP2016138142A (en) | Methods of providing weight loss therapy in patients with major depression | |
| US20210085638A1 (en) | Terpene Control in Scaleable Cannabinoid Medicinal Formulations | |
| JP2017510607A5 (en) | ||
| Paterson et al. | A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment | |
| KR20150038072A (en) | Treatment of Multiple Sclerosis with Combination of Laquinimod and Fampridine | |
| DK2747561T3 (en) | TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESIS | |
| Mallhi et al. | Chloroquine and hydroxychloroquine in COVID-19: practice implications for healthcare professionals | |
| CN103316346B (en) | Treat the pharmaceutical composition of epilepsy | |
| CN103301115A (en) | Medicine composition for treating epilepsy | |
| CN107308181A (en) | Treat the compound medicinal formulation of refractory hypertension | |
| CN103301124A (en) | Medicine composition for treating epilepsy | |
| CN103315989A (en) | Pharmaceutical composition | |
| CN103301100B (en) | A kind of compound medicament composition | |
| CN103301464B (en) | Pharmaceutical composition | |
| CN103315987B (en) | A kind of pharmaceutical composition for treating epilepsy | |
| CN105326840B (en) | A kind of combination medicine containing qinghaosu | |
| Falières | Do we really need opioids in anesthesia? | |
| RU2013124994A (en) | COMBINATION OF BEVACISUMUMAB AND 2,2-DIMETHYL-N - ((S) -6-OXO-6,7-DIHYDRO-5H-DIBENZO [b, d] AZEPIN-7-IL) -N '- (2,2,3 , 3,3-PENTAFTOR-PROPYL) -MALONAMIDE FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| CN101327217A (en) | Use of indinavir sulfate and chloroquine in preparing compound antimalarial medicament | |
| Teppone | The phase dynamics of the COVID-19 pandemic: a systematic analysis of 213 Countries and Territories | |
| Ahmed | Sedative Agents for Clinically Ill Patients | |
| US20230158020A1 (en) | Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2) | |
| RU2788450C2 (en) | Methods for weight loss therapy in patients with dominant depression | |
| Pauff et al. | Reversible posterior leukoencephalopathy syndrome due to carfilzomib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171120 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: WEIHAI DIZHIYA PHARMACEUTICAL Co.,Ltd. Applicant before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191115 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210826 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |